These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 26202950)
21. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243 [TBL] [Abstract][Full Text] [Related]
22. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678 [TBL] [Abstract][Full Text] [Related]
23. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782 [TBL] [Abstract][Full Text] [Related]
24. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152 [TBL] [Abstract][Full Text] [Related]
25. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523 [TBL] [Abstract][Full Text] [Related]
26. Venetoclax-based Rational Combinations are Effective in Models of Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831 [TBL] [Abstract][Full Text] [Related]
27. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952 [TBL] [Abstract][Full Text] [Related]
28. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085 [TBL] [Abstract][Full Text] [Related]
29. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850 [TBL] [Abstract][Full Text] [Related]
30. Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. Wood L; Huang M; Zeki J; Gong M; Taylor J; Shimada H; Chiu B J Pediatr Surg; 2021 Jul; 56(7):1199-1202. PubMed ID: 33838899 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192 [TBL] [Abstract][Full Text] [Related]
32. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395 [TBL] [Abstract][Full Text] [Related]
33. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines. Ikegaki N; Hicks SL; Regan PL; Jacobs J; Jumbo AS; Leonhardt P; Rappaport EF; Tang XX Int J Oncol; 2014 Jan; 44(1):35-43. PubMed ID: 24173829 [TBL] [Abstract][Full Text] [Related]
34. High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Peirce SK; Findley HW Oncol Rep; 2009 Dec; 22(6):1443-9. PubMed ID: 19885598 [TBL] [Abstract][Full Text] [Related]
35. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764 [TBL] [Abstract][Full Text] [Related]
36. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398 [TBL] [Abstract][Full Text] [Related]
37. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190 [TBL] [Abstract][Full Text] [Related]
38. Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374 [No Abstract] [Full Text] [Related]
39. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633 [TBL] [Abstract][Full Text] [Related]
40. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]